Metabolic & Cardiometabolic
ezetimibe decreases Alzheimer's disease
Part of: 💊 ezetimibe
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
The Norwitz-cited 'ezetimibe protects the brain' signal: a real 14-3-3/hexokinase autophagy mechanism (worm/cell) PLUS a retrospective '7x lower dementia' association - almost certainly inflated by healthy-user/indication confounding; a 2026 review even hints at HIGHER cognitive risk. Net: intriguing hypothesis, NOT a finding. Do not rely on it.
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| n/a 2007 ClinicalTrials.gov | RCT | tested-null | low | No completed ezetimibe RCT for AD/dementia exists (only a terminated pitavastatin study); AD claim rests solely on MR + in-silico/EHR |
| Nordestgaard 2025 · Alzheimers Dement | observational | mixed | moderate | [FT-verified 2026-08-19] Drug-target MR of NPC1L1 (ezetimibe's target) in 1,091,775 people. Headline is ALL-CAUSE dementia, not AD: one-sample MR OR 0.18 (0.12-0.25) per 1 mmol/L lower non-HDL-C. AD specifically is the WEAK arm: 'The nominal effects were larger for vascular dementia and unspecified dementia than for AD', and on the LDL-as-exposure sensitivity 'Results were directionally consistent with main analyses except for AD, which was null in these analyses'. Prior correction: the vascular-dementia arm was NOT significant either - 'most results for vascular dementia had P values > 0.05' (power, n~1700). Two further caveats specific to NPC1L1: the IHD positive control FAILED for NPC1L1 in two-sample MR ('...through all analyses except for NPC1L1 in two-sample MR', attributed to weak instrument bias; single variant, F=27 in UK Biobank), and the authors state 'this study investigates the effect of genetic targets and not the effect of prescribed medications on dementia risk'. AD-subtype point estimates live in Figure 3 and were not readable from the XML. Net for an AD-specific claim: mixed, and thinner than the abstract reads. |
| Williams 2020 2020 · Ann Neurol | observational | tested-null | moderate | [FT-verified] Drug-target MR, 24,718 AD cases / 56,685 controls: the NPC1L1 (ezetimibe) model 'did not provide clear evidence to suggest that the use of the corresponding lipid-lowering drug classes would affect AD risk', with NPC1L1 and APOB point estimates 'on the side of risk, but confidence intervals (CIs) in all instances were wide and included the null'. Interpretation: 'We did not identify genetic support for the repurposing of statins, ezetimibe, or mipomersen for AD prevention.' This is an IMPRECISE null on a weak cis instrument — not a demonstration that ezetimibe has no effect — so it stays tested-null rather than converting to contradicts under the directional-claim rule; note the point estimate ran opposite to the claimed protection. The genome-wide general-LDL-C instrument, by contrast, was a well-powered null (IGAP IVW OR 0.98, 0.88-1.10). |
| Gyimesi G 2025 · Physiol Rev | mechanism | contradicts | low | [null on reduces-claim = contradicts] Broad review of the entire SLC transporter superfamily (464 SLCs); mentions neurodegenerative disorders only generically among diseases linked to SLC dysfunction, with no ezetimibe/NPC1L1/AD-specific da |
| Geifman 2017 · Alzheimers Res Ther | observational | tested-null | low | Statin exposure linked to lower AD risk in subgroups but general-population trials null |
| Klionsky DJ 2021 · Autophagy | mechanism | contradicts | low | [null on reduces-claim = contradicts] Methodological guidelines for autophagy assays; no content on ezetimibe or Alzheimer's disease. |
| Jiménez-Sánchez A 2022 · Nutrients | observational | tested-null | low | [null on reduces-claim = contradicts] Narrative review of extra virgin olive oil's cardiovascular/metabolic benefits; no mention of ezetimibe, cholesterol absorption inhibitors, or Alzheimer's/dementia outcomes. |
| Ganne A, et al. 2024 · Aging Biol | mechanism | supports | low | [FT-verified] FT: proteomics+in-silico docking+retrospective EHR not outcome study; 'sevenfold' is hypothesis-grade, title overstates |
| Waters 2010 · J Cardiol | RCT | contradicts | moderate | Statin RCTs did not slow early Alzheimer's; cholesterol-lowering AD benefit not demonstrated |
| McGuinness 2016 · Cochrane Database Syst Rev | meta-analysis | contradicts | high | Cochrane: statins in late life do not prevent dementia/cognitive decline (indirect to ezetimibe) |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.